Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. (February 2014)
- Record Type:
- Journal Article
- Title:
- Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. (February 2014)
- Main Title:
- Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention
- Authors:
- Skala, Katrin
Caputo, Fabio
Mirijello, Antonio
Vassallo, Gabriele
Antonelli, Mariangela
Ferrulli, Anna
Walter, Henriette
Lesch, Otto
Addolorato, Giovanni - Abstract:
- <abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> <ext-link ext-link-type="uri" xlink:href="http://informahealthcare.com/action/doSearch?type=advanced&amp;displaySummary=true&amp;displaySummary=true&amp;field1=keywords&amp;text1=Sodium oxybate&amp;logicalOpe1=OR&amp;field2=articletitle&amp;text2=Sodium oxybate&amp;logicalOpe2=AND&amp;field3=all&amp;text3=&amp;search=Search&amp;categoryId=41010274&amp;categoryId=40002416&amp;categoryId=40004717&amp;categoryId=40004717&amp;filter=multiple&amp;AfterMonth=1&amp;AfterYear=&amp;BeforeMonth=12&amp;BeforeYear=&amp;sortBy=date&amp;nh=20" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">Sodium oxybate</ext-link> (SMO) has been shown to be safe and effective in the treatment of patients with alcohol use disorders (AUDs); it was approved in Italy and Austria for the treatment of alcohol withdrawal syndrome and for relapse prevention. The focus of this review is to discuss the clinical evidence on the therapeutic potential of SMO for AUDs.</p> <p> <bold> <italic>Areas covered:</italic> </bold> This review covers the studies in patients with alcohol withdrawal syndrome who received SMO for the treatment of withdrawal symptoms and the studies in patients with AUDs who received SMO to achieve total alcohol abstinence, reduction of alcohol intake, and relapse prevention. Relevant medical literature on SMO was identified by searching databases including MEDLINE and<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> <ext-link ext-link-type="uri" xlink:href="http://informahealthcare.com/action/doSearch?type=advanced&amp;displaySummary=true&amp;displaySummary=true&amp;field1=keywords&amp;text1=Sodium oxybate&amp;logicalOpe1=OR&amp;field2=articletitle&amp;text2=Sodium oxybate&amp;logicalOpe2=AND&amp;field3=all&amp;text3=&amp;search=Search&amp;categoryId=41010274&amp;categoryId=40002416&amp;categoryId=40004717&amp;categoryId=40004717&amp;filter=multiple&amp;AfterMonth=1&amp;AfterYear=&amp;BeforeMonth=12&amp;BeforeYear=&amp;sortBy=date&amp;nh=20" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">Sodium oxybate</ext-link> (SMO) has been shown to be safe and effective in the treatment of patients with alcohol use disorders (AUDs); it was approved in Italy and Austria for the treatment of alcohol withdrawal syndrome and for relapse prevention. The focus of this review is to discuss the clinical evidence on the therapeutic potential of SMO for AUDs.</p> <p> <bold> <italic>Areas covered:</italic> </bold> This review covers the studies in patients with alcohol withdrawal syndrome who received SMO for the treatment of withdrawal symptoms and the studies in patients with AUDs who received SMO to achieve total alcohol abstinence, reduction of alcohol intake, and relapse prevention. Relevant medical literature on SMO was identified by searching databases including MEDLINE and EMBASE (searches last updated 20 September 2013), bibliographies from published literature, clinical trial registries/databases, and websites.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> SMO has proved safe and effective in the treatment of alcohol withdrawal syndrome and in the prevention of relapses. Craving for and abuse of SMO have been reported, in particular in some subtypes of alcoholic patients, e.g., those affected by co-addiction and/or psychiatric comorbidity. Future multicenter, multinational, randomized clinical trials should be useful to optimize the treatments in relation with patients' characteristics, for example, pharmacogenetic, neurobiological, and psychological.</p> </abstract> … (more)
- Is Part Of:
- Expert opinion on pharmacotherapy. Volume 15:Number 2(2014)
- Journal:
- Expert opinion on pharmacotherapy
- Issue:
- Volume 15:Number 2(2014)
- Issue Display:
- Volume 15, Issue 2 (2014)
- Year:
- 2014
- Volume:
- 15
- Issue:
- 2
- Issue Sort Value:
- 2014-0015-0002-0000
- Page Start:
- 245
- Page End:
- 257
- Publication Date:
- 2014-02
- Subjects:
- Chemotherapy -- Periodicals
615.5805 - Journal URLs:
- http://informahealthcare.com/ ↗
http://www.tandfonline.com/toc/ieop20/current ↗
http://informahealthcare.com ↗
http://titania.ashley-pub.com/vl=5663459/cl=52/nw=1/rpsv/journal/journal6_home.htm ↗ - DOI:
- 10.1517/14656566.2014.863278 ↗
- Languages:
- English
- ISSNs:
- 1465-6566
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002956
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3740.xml